STAT

STAT+: Pharmalittle: Moderna pays NIH for Covid vaccine technique; first trial over Zantac cancer claims is postponed

Moderna has paid $400 million to the U.S. government for the rights to a chemical technique used in its successful Covid-19 vaccines.
Source: Alex Hogan/STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream and ). And what about you? Depending upon your location, this may be an opportunity to enjoy the great outdoors, but if not, you could curl up in front of the telly and binge-watch or dive into an e-book. Of course, it is never too early to plan a spring break. Or reach out to someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Pfizer’s DTC Platform, Sandoz’s Feud With A U.K. Trade Group, And More
Pfizer filed a trademark application last month for a website and app providing medical information and mail-order pharmacy and telehealth services to U.S. patients.
STAT1 min read
STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.

Related Books & Audiobooks